...
首页> 外文期刊>American Journal of Surgical Pathology >Are Enterocolic Mucosal Mast Cell Aggregates Clinically Relevant in Patients Without Suspected or Established Systemic Mastocytosis?
【24h】

Are Enterocolic Mucosal Mast Cell Aggregates Clinically Relevant in Patients Without Suspected or Established Systemic Mastocytosis?

机译:是否是患者临床相关的肠贯致粘膜粘液肥料细胞,没有疑似或建立全身性乳细胞症的患者?

获取原文
获取原文并翻译 | 示例

摘要

The World Health Organization considers enterocolic mast cell aggregates with atypical morphologic and/or immunohistochemical features diagnostic of systemic mastocytosis mostly because published data are heavily influenced by inclusion of symptomatic patients with systemic disease. We occasionally encounter atypical mast cells in gastrointestinal biopsy samples from patients in whom systemic mastocytosis is not suspected. The aim of this study was to describe the clinicopathologic features and implications of atypical enterocolic mast cell aggregates in 16 patients without suspected or established systemic mastocytosis. Mast cell infiltrates were assessed for morphology, distribution, associated inflammatory cells, and CD117 and CD25 immunoexpression. Most (63%) patients were women; 15 underwent endoscopic examination for screening (n = 7), abdominal pain (n = 3), diarrhea (n = 3), changing bowel habits (n = 1), and dysphagia (n = 1). Mast cell aggregates were detected in 1 colectomy specimen for cancer. Colonic involvement was most common (n = 14) and resulted in polypoid (n = 10), edematous (n = 2), or normal (n = 3) mucosae. All cases featured CD117/CD25(+), ovoid mast cells concentrated beneath the epithelium, or diffusely involving the entire mucosal thickness. Eosinophils were numerous and obscured mast cells in 63% of cases. Spontaneous resolution of symptoms occurred in all patients (mean follow-up: 54 mo), and asymptomatic patients remained symptom-free (mean follow-up: 17 mo). Of 4 patients evaluated for systemic mastocytosis, 3 had negative bone marrow biopsies and one lacked a KIT mutation in peripheral blood. We conclude that, although careful clinical assessment of patients with incidental enterocolic mast cell aggregates is reasonable, labeling them with a systemic hematologic disorder may not be justified.
机译:世界卫生组织认为具有非典型形态学和/或免疫组织化学特征的肠贯魅力肥大细胞骨细胞诊断主要是由于发表的数据含有症状患者的全身疾病患者受到严重影响。我们偶尔会遇到来自患者的胃肠生物检查样本中的非典型桅杆细胞,其患者没有怀疑患者。本研究的目的是描述16例没有疑似或建立全身性乳细胞症的16例患者的临床病理特征和非典型肠溶肥肥剧细胞的影响。评估肥大细胞浸润,用于形态,分布,相关炎症细胞和CD117和CD25免疫表达。大多数(63%)患者是女性; 15进行筛选的内窥镜检查(n = 7),腹痛(n = 3),腹泻(n = 3),改变肠习惯(n = 1)和吞咽困难(n = 1)。在1个联合肌切离术标本中检测到肥大细胞骨料用于癌症。结肠受累是最常见的(n = 14)并导致息肉(n = 10),水肿(n = 2)或正常(n = 3)粘膜。所有案例特征在上皮下浓缩的卵形桅杆细胞,或弥漫涉及整个粘膜厚度。嗜酸性粒细胞在63%的病例中是众多和模糊的肥大细胞。所有患者发生症状的自发分辨率(平均随访:54mO),无症状患者仍然存在症状(平均随访:17 mo)。对于4例患者,评估了全身乳细胞诱变症,3例具有负骨髓活检,一个缺乏外周血的试剂盒突变。我们得出结论,虽然仔细临床评估偶然的肠溶桅杆细胞聚集体是合理的,但用全身性血液疾病标记它们可能不会有合理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号